| Literature DB >> 32548408 |
Wei Huang1, Qi He1, Zhen-Ru Zhou1, Hai-Bin He1, Ren-Wang Jiang1.
Abstract
Puerarin (PU) is the most abundant isoflavone from the root of Pueraria lobata and exhibits a broad range of pharmacological activities. However, poor water solubility and low bioavailability limit its use. Enzymatic transglycosylation is emerging as a new strategy to improve the pharmacodynamic and pharmacokinetic properties of natural products for drug development. In this study, three PU glucosides (PU-G, PU-2G, and PU-3G) were synthesized by using a cyclodextrin glucanotransferase from Bacillus licheniformis with PU as the acceptor and α-cyclodextrin as the sugar donor. The transglycosylation products were isolated and structurally identified by mass spectrometry and nuclear magnetic resonance. The water solubilities of PU-G, PU-2G, and PU-3G were 15.6, 100.9, and 179.1 times higher than that of PU, respectively. Moreover, the antiosteoporosis activities of these glucosides were tested, and PU-G was found to show much more potent antiosteoporosis activity as compared to the original PU.Entities:
Year: 2020 PMID: 32548408 PMCID: PMC7271355 DOI: 10.1021/acsomega.0c00950
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1(A) HPLC–DAD chromatograms of the transglycosylated reaction mixture using PU as the substrate. (B) HR-ESI-MS analysis of products PU-G, PU-2G, PU-3G, and PU-4G.
Figure 2Optimization of the transglycosylated reaction conditions: (A) temperature; (B) pH; (C) reaction time; (D) sugar donors; (E) divalent metal ions; and (F) ratio of α-CD/PU.
Figure 3Outline of the PU glycosylation by CD glucanotransferase and the chemical structures of the PU glucosides.
1H and 13C NMR Data of PU and PU-3G
| | |||||
|---|---|---|---|---|---|
| carbon no. | (δH) | (δC) | (δH) | (δC) | |
| 2 | 152.67 | 152.57 | |||
| 3 | 122.53 | 122.59 | |||
| 4 | 174.90 | 174.91 | |||
| 5 | 7.94 (1H, | 126.23 | 7.93 (1H, | 126.31 | |
| 6 | 6.99 (1H, | 115.02 | 7.00 (1H, | 115.02 | |
| 7 | 161.12 | 161.83 | |||
| 8 | 112.66 | 112.30 | |||
| 9 | 157.16 | 157.20 | |||
| 10 | 116.56 | 116.56 | |||
| 1′ | 7.39 (1H, | 123.07 | 7.39 (1H, | 123.10 | |
| 2′ | 6.80 (1H, | 130.04 | 6.78 (1H, | 130.05 | |
| 3′ | 114.97 | 115.02 | |||
| 4′ | 6.80 (1H, | 156.31 | 6.78 (1H, | 156.31 | |
| 5′ | 114.97 | 115.02 | |||
| 6′ | 7.39 (1H, | 130.04 | 7.39 (1H, | 130.05 | |
| 1″ | 4.81 (1H, | 73.43 | 4.84 (1H, | 73.43 | |
| 2″ | 70.76 | 71.77 | |||
| 3″ | 78.77 | 78.52 | |||
| 4″ | |||||
| 5″ | 81.87 | 80.49 | |||
| 6″ | 61.45 | 60.92 | |||
| α- | 1‴ | 5.01 (1H, | 100.65 | ||
| 2‴ | 70.33 | ||||
| 3‴ | 73.48 | ||||
| 4‴ | |||||
| 5‴ | 73.12 | ||||
| 6‴ | 60.83 | ||||
| α- | 1″″ | 5.02 (1H, | 100.81 | ||
| 2″″ | 70.30 | ||||
| 3″″ | 73.33 | ||||
| 4″″ | |||||
| 5″″ | 72.56 | ||||
| 6″″ | 60.83 | ||||
| α- | 1″‴ | 5.09 (1H, | 100.81 | ||
| 2″‴ | 69.95 | ||||
| 3″‴ | 73.20 | ||||
| 4″‴ | 60.92 | ||||
| 5″‴ | 72.11 | ||||
| 6″‴ | 60.28 | ||||
Water Solubility of PU and Its Glucosides
| compound | solubility
in water | relative solubility |
|---|---|---|
| 5.24 ± 1.32 | 1.0 | |
| 81.76 ± 5.36 | 15.6 | |
| 528.54 ± 18.24 | 100.9 | |
| 938.26 ± 25.53 | 179.1 |
Mean ± SD.
Figure 4Antiosteoporosis activity of PU and its glucosides. (A) Effect of PU and its glucosides on the ALP activity. (B) Effect of PU and its glucosides on the expression of runx2. The data presented are mean ± standard error of the mean (n = 3). *, P < 0.05, **, P < 0.01, and ***, P < 0.001 are relative to the control group.